Characterization of SH2D1A Missense Mutations Identified in X-linked Lymphoproliferative Disease Patients

Massimo Morra, Maria Simarro-Grande, Margarita Martin, Alice Siau In Chen, Arpad Lanyi, Olin Silander, Silvia Calpe, Jack Davis, Tony Pawson, Michael J. Eck, Janos Sumegi, Pablo Engel, Shun Cheng Li, Cox Terhorst

Research output: Contribution to journalArticle

63 Citations (Scopus)

Abstract

X-linked lymphoproliferative disease (XLP) is a primary immunodeficiency characterized by extreme susceptibility to Epstein-Barr virus. The XLP disease gene product SH2D1A (SAP) interacts via its SH2 domain with a motif (TIYXXV) present in the cytoplasmic tail of the cell-surface receptors CD150/SLAM, CD84, CD229/Ly-9, and CD244/2B4. Characteristically, the SH2D1A three-pronged interaction with Tyr281 of CD150 can occur in absence of phosphorylation. Here we analyze the effect of SH2D1A protein missense mutations identified in 10 XLP families. Two sets of mutants were found: (i) mutants with a marked decreased protein half-life (eg. Y7C, S28R, Q99P, P101L, V102G, and X129R) and (ii) mutants with structural changes that differently affect the interaction with the four receptors. In the second group, mutations that disrupt the interaction between the SH2D1A hydrophobic cleft and Val +3 of its binding motif (e.g. T68I) and mutations that interfere with the SH2D1A phosphotyrosine-binding pocket (e.g. C42W) abrogated SH2D1A binding to all four receptors. Surprisingly, a mutation in SH2D1A able to interfere with Thr -2 of the CD150 binding motif (mutant T53I) severely impaired non-phosphotyrosine interactions while preserving unaffected the binding of SH2D1A to phosphorylated CD150. Mutant T53I, however, did not bind to CD229 and CD224, suggesting that SH2D1A controls several critical signaling pathways in T and natural killer cells. Because no correlation is present between identified types of mutations and XLP patient clinical presentation, additional unidentified genetic or environmental factors must play a strong role in XLP disease manifestations.

Original languageEnglish (US)
Pages (from-to)36809-36816
Number of pages8
JournalJournal of Biological Chemistry
Volume276
Issue number39
DOIs
StatePublished - Sep 28 2001

Fingerprint

Lymphoproliferative Disorders
Missense Mutation
Mutation
Phosphotyrosine
Natural Killer T-Cells
Critical Pathways
src Homology Domains
Cell Surface Receptors
Human Herpesvirus 4
Half-Life
Phosphorylation
Viruses
Proteins
Genes

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Cell Biology

Cite this

Morra, M., Simarro-Grande, M., Martin, M., Chen, A. S. I., Lanyi, A., Silander, O., ... Terhorst, C. (2001). Characterization of SH2D1A Missense Mutations Identified in X-linked Lymphoproliferative Disease Patients. Journal of Biological Chemistry, 276(39), 36809-36816. https://doi.org/10.1074/jbc.M101305200

Characterization of SH2D1A Missense Mutations Identified in X-linked Lymphoproliferative Disease Patients. / Morra, Massimo; Simarro-Grande, Maria; Martin, Margarita; Chen, Alice Siau In; Lanyi, Arpad; Silander, Olin; Calpe, Silvia; Davis, Jack; Pawson, Tony; Eck, Michael J.; Sumegi, Janos; Engel, Pablo; Li, Shun Cheng; Terhorst, Cox.

In: Journal of Biological Chemistry, Vol. 276, No. 39, 28.09.2001, p. 36809-36816.

Research output: Contribution to journalArticle

Morra, M, Simarro-Grande, M, Martin, M, Chen, ASI, Lanyi, A, Silander, O, Calpe, S, Davis, J, Pawson, T, Eck, MJ, Sumegi, J, Engel, P, Li, SC & Terhorst, C 2001, 'Characterization of SH2D1A Missense Mutations Identified in X-linked Lymphoproliferative Disease Patients', Journal of Biological Chemistry, vol. 276, no. 39, pp. 36809-36816. https://doi.org/10.1074/jbc.M101305200
Morra, Massimo ; Simarro-Grande, Maria ; Martin, Margarita ; Chen, Alice Siau In ; Lanyi, Arpad ; Silander, Olin ; Calpe, Silvia ; Davis, Jack ; Pawson, Tony ; Eck, Michael J. ; Sumegi, Janos ; Engel, Pablo ; Li, Shun Cheng ; Terhorst, Cox. / Characterization of SH2D1A Missense Mutations Identified in X-linked Lymphoproliferative Disease Patients. In: Journal of Biological Chemistry. 2001 ; Vol. 276, No. 39. pp. 36809-36816.
@article{0126048effdb422eb7d28aef024e05bd,
title = "Characterization of SH2D1A Missense Mutations Identified in X-linked Lymphoproliferative Disease Patients",
abstract = "X-linked lymphoproliferative disease (XLP) is a primary immunodeficiency characterized by extreme susceptibility to Epstein-Barr virus. The XLP disease gene product SH2D1A (SAP) interacts via its SH2 domain with a motif (TIYXXV) present in the cytoplasmic tail of the cell-surface receptors CD150/SLAM, CD84, CD229/Ly-9, and CD244/2B4. Characteristically, the SH2D1A three-pronged interaction with Tyr281 of CD150 can occur in absence of phosphorylation. Here we analyze the effect of SH2D1A protein missense mutations identified in 10 XLP families. Two sets of mutants were found: (i) mutants with a marked decreased protein half-life (eg. Y7C, S28R, Q99P, P101L, V102G, and X129R) and (ii) mutants with structural changes that differently affect the interaction with the four receptors. In the second group, mutations that disrupt the interaction between the SH2D1A hydrophobic cleft and Val +3 of its binding motif (e.g. T68I) and mutations that interfere with the SH2D1A phosphotyrosine-binding pocket (e.g. C42W) abrogated SH2D1A binding to all four receptors. Surprisingly, a mutation in SH2D1A able to interfere with Thr -2 of the CD150 binding motif (mutant T53I) severely impaired non-phosphotyrosine interactions while preserving unaffected the binding of SH2D1A to phosphorylated CD150. Mutant T53I, however, did not bind to CD229 and CD224, suggesting that SH2D1A controls several critical signaling pathways in T and natural killer cells. Because no correlation is present between identified types of mutations and XLP patient clinical presentation, additional unidentified genetic or environmental factors must play a strong role in XLP disease manifestations.",
author = "Massimo Morra and Maria Simarro-Grande and Margarita Martin and Chen, {Alice Siau In} and Arpad Lanyi and Olin Silander and Silvia Calpe and Jack Davis and Tony Pawson and Eck, {Michael J.} and Janos Sumegi and Pablo Engel and Li, {Shun Cheng} and Cox Terhorst",
year = "2001",
month = "9",
day = "28",
doi = "10.1074/jbc.M101305200",
language = "English (US)",
volume = "276",
pages = "36809--36816",
journal = "Journal of Biological Chemistry",
issn = "0021-9258",
publisher = "American Society for Biochemistry and Molecular Biology Inc.",
number = "39",

}

TY - JOUR

T1 - Characterization of SH2D1A Missense Mutations Identified in X-linked Lymphoproliferative Disease Patients

AU - Morra, Massimo

AU - Simarro-Grande, Maria

AU - Martin, Margarita

AU - Chen, Alice Siau In

AU - Lanyi, Arpad

AU - Silander, Olin

AU - Calpe, Silvia

AU - Davis, Jack

AU - Pawson, Tony

AU - Eck, Michael J.

AU - Sumegi, Janos

AU - Engel, Pablo

AU - Li, Shun Cheng

AU - Terhorst, Cox

PY - 2001/9/28

Y1 - 2001/9/28

N2 - X-linked lymphoproliferative disease (XLP) is a primary immunodeficiency characterized by extreme susceptibility to Epstein-Barr virus. The XLP disease gene product SH2D1A (SAP) interacts via its SH2 domain with a motif (TIYXXV) present in the cytoplasmic tail of the cell-surface receptors CD150/SLAM, CD84, CD229/Ly-9, and CD244/2B4. Characteristically, the SH2D1A three-pronged interaction with Tyr281 of CD150 can occur in absence of phosphorylation. Here we analyze the effect of SH2D1A protein missense mutations identified in 10 XLP families. Two sets of mutants were found: (i) mutants with a marked decreased protein half-life (eg. Y7C, S28R, Q99P, P101L, V102G, and X129R) and (ii) mutants with structural changes that differently affect the interaction with the four receptors. In the second group, mutations that disrupt the interaction between the SH2D1A hydrophobic cleft and Val +3 of its binding motif (e.g. T68I) and mutations that interfere with the SH2D1A phosphotyrosine-binding pocket (e.g. C42W) abrogated SH2D1A binding to all four receptors. Surprisingly, a mutation in SH2D1A able to interfere with Thr -2 of the CD150 binding motif (mutant T53I) severely impaired non-phosphotyrosine interactions while preserving unaffected the binding of SH2D1A to phosphorylated CD150. Mutant T53I, however, did not bind to CD229 and CD224, suggesting that SH2D1A controls several critical signaling pathways in T and natural killer cells. Because no correlation is present between identified types of mutations and XLP patient clinical presentation, additional unidentified genetic or environmental factors must play a strong role in XLP disease manifestations.

AB - X-linked lymphoproliferative disease (XLP) is a primary immunodeficiency characterized by extreme susceptibility to Epstein-Barr virus. The XLP disease gene product SH2D1A (SAP) interacts via its SH2 domain with a motif (TIYXXV) present in the cytoplasmic tail of the cell-surface receptors CD150/SLAM, CD84, CD229/Ly-9, and CD244/2B4. Characteristically, the SH2D1A three-pronged interaction with Tyr281 of CD150 can occur in absence of phosphorylation. Here we analyze the effect of SH2D1A protein missense mutations identified in 10 XLP families. Two sets of mutants were found: (i) mutants with a marked decreased protein half-life (eg. Y7C, S28R, Q99P, P101L, V102G, and X129R) and (ii) mutants with structural changes that differently affect the interaction with the four receptors. In the second group, mutations that disrupt the interaction between the SH2D1A hydrophobic cleft and Val +3 of its binding motif (e.g. T68I) and mutations that interfere with the SH2D1A phosphotyrosine-binding pocket (e.g. C42W) abrogated SH2D1A binding to all four receptors. Surprisingly, a mutation in SH2D1A able to interfere with Thr -2 of the CD150 binding motif (mutant T53I) severely impaired non-phosphotyrosine interactions while preserving unaffected the binding of SH2D1A to phosphorylated CD150. Mutant T53I, however, did not bind to CD229 and CD224, suggesting that SH2D1A controls several critical signaling pathways in T and natural killer cells. Because no correlation is present between identified types of mutations and XLP patient clinical presentation, additional unidentified genetic or environmental factors must play a strong role in XLP disease manifestations.

UR - http://www.scopus.com/inward/record.url?scp=0035965317&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035965317&partnerID=8YFLogxK

U2 - 10.1074/jbc.M101305200

DO - 10.1074/jbc.M101305200

M3 - Article

VL - 276

SP - 36809

EP - 36816

JO - Journal of Biological Chemistry

JF - Journal of Biological Chemistry

SN - 0021-9258

IS - 39

ER -